•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera’s BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab). Dr. Reddy’s will gain exclusive rights to commercialize…
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55 billion over the next four years in the United States, allocated to manufacturing, research and development, and technology. This represents a 25% increase compared to the previous four years, building on the company’s increased investment…
•
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the US Food and Drug Administration (FDA) to market its Tremfya (guselkumab) as a treatment for moderately to severely active Crohn’s disease (CD). This IL-23 inhibitor now offers both subcutaneous (SC) and intravenous (IV) induction options…
•
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from the US FDA for its nipocalimab as a treatment for adult patients with moderate-to-severe Sjögren’s disease (SjD). This designation follows the monoclonal antibody’s Breakthrough Therapy Designation (BTD) received from the agency late last year. Mechanism…
•
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab), has been accepted for review by China’s National Medical Products Administration (NMPA). This marks a significant step forward in the development and commercialization of this anti-TNF alpha…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting significant revenue growth. In Q4, the company reported revenues of USD187 million, marking a 134.7% year-on-year increase. For the entire year, revenues surged by 120.0% to USD627 million. Carvykti’s Impact on RevenueThe BCMA-directed chimeric antigen…
•
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization of HexaBody-CD38 (GEN3014). Consequently, clinical development of the drug will be terminated. The decision was based on…
•
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in China to alleviate depressive symptoms in adult depression patients. The announcement comes after a swift approval by China’s National Medical Products Administration (NMPA) in April 2023. Spravato’s novel mechanism and rapid resultsSpravato is the first…
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the retirement of Yihao Zhang, president and CEO of its China operations, effective July 1, 2025. Will Song, a Johnson & Johnson veteran with over 20 years of experience, will join the company on April 1,…
•
Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC 7s ultrasonic scalpel instrument in China, marking a milestone with local production at its Suzhou plant. Product HighlightsThe HARMONIC 7s features an innovative built-in intelligent chip and proprietary next-generation adaptive tissue algorithm (ATT), enabling continuous…
•
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval from China’s National Medical Products Administration (NMPA) for treating moderate to severe active Crohn’s disease (CD) in adults who have not responded adequately to traditional therapies or biologics. Drug ProfileTremfya, an interleukin-23 monoclonal antibody, was…
•
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson & Johnson’s (J&J, NYSE: JNJ) autoimmune drug Stelara (ustekinumab), in the US. The drug, developed by South Korea’s Samsung Bioepis Co., Ltd., is approved for the same chronic inflammatory disease indications as the originator. Licensing DealSandoz…
•
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase III ASTRO study of its Tremfya (guselkumab) subcutaneous (SC) induction therapy for adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO). The data…
•
France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate for extraintestinal pathogenic E. coli failed to meet expectations in a Phase III study. An independent data monitoring committee (IDMC) determined that the vaccine was insufficiently effective at preventing invasive E. coli disease (IED) compared…
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care business Cerenovus. According to the Financial Times, the potential deal could be worth between USD1 billion and USD1.5 billion. Background of CerenovusJ&J established Cerenovus as a neurovascular business unit in 2017. This was done through…
•
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), has recently departed from the Chinese company. He will now serve as Executive Director of External Innovation at AbbVie. Dr. Chen Dong’s Background and Contributions at HengruiDr. Chen Dong studied at Wuhan…
•
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin, a biosimilar version of Johnson & Johnson (J&J)’s auto-immune disease drug Stelara (ustekinumab), has been accepted for review by the National Medical Products Administration (NMPA). The Chinese firm is seeking approval for its use in…
•
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments to its leadership team. The company has appointed a new general manager and a new vice president. New General ManagerAs of March 1, 2025, Mr. Chen Jian will take on the role of head of…
•
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement with Intas Pharmaceuticals Ltd., granting the Indian firm exclusive commercialization rights to its BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab), in the United States. Details of the AgreementUnder the terms of the…
•
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306 and BAT2506 have been accepted for review by China’s National Medical Products Administration (NMPA) and the European Medicines Agency (EMA), respectively. BAT2306 is a biosimilar version of Novartis’ (NYSE: NVS) Cosentyx (secukinumab), while BAT2506 is…